Stargardt Disease Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Type, By Distribution Channel, By Region & Competition, 2020-2030F
세계 스타가르트병 치료제 시장은 2024년 2억 275만 달러로 평가되며, 2030년까지 CAGR 7.50%로 예측 기간 동안 괄목할 만한 성장이 예상됩니다.
유전성 안질환인 스타가르트병은 중심시력을 선명하게 하는 데 중요한 역할을 하는 황반에 악영향을 미칩니다. 이 질환은 보통 어린 시절이나 청소년기에 발병하여 점차 시력이 저하됩니다. 현재 스타가르트병에 대한 승인된 치료법은 없지만, 병을 관리하고 진행을 막을 수 있는 치료법 개발은 큰 진전을 보이고 있습니다. 예를 들어, 세계보건기구(WHO)는 2023년 전 세계 22억 명 이상이 시력 장애를 앓고 있으며, 최소 10억 명은 예방이 가능하거나 치료할 수 있다고 보고하고 있습니다. 실명과 시력 상실의 주요 원인은 굴절 이상과 백내장이며, 안과 의료 및 예방 조치의 개선이 시급하다는 것을 강조하고 있습니다.
| 시장 개요 |
| 예측 기간 |
2026-2030년 |
| 시장 규모 : 2024년 |
2억 275만 달러 |
| 시장 규모 : 2030년 |
3억 1,041만 달러 |
| CAGR : 2025-2030년 |
7.50% |
| 급성장 부문 |
LBS-008 |
| 최대 시장 |
북미 |
시장 촉진요인
보급률 및 인지도 향상
주요 시장 과제
질병 메커니즘에 대한 이해 부족
주요 시장 동향
유전자 치료의 획기적인 발전
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 스타가르트병 치료제 시장 전망
- 시장 규모 및 예측
- 시장 점유율과 예측
- 약물 유형별(LBS-008, Emixustat)
- 유통 채널별(병원 약국, 소매 약국, 온라인 약국)
- 지역별
- 기업별(2024)
- 제품 시장 맵
제6장 북미의 스타가르트병 치료제 시장 전망
- 시장 규모 및 예측
- 시장 점유율과 예측
- 북미 : 국가별 분석
제7장 유럽의 스타가르트병 치료제 시장 전망
- 시장 규모 및 예측
- 시장 점유율과 예측
- 유럽 : 국가별 분석
제8장 아시아태평양의 스타가르트병 치료제 시장 전망
- 시장 규모 및 예측
- 시장 점유율과 예측
- 아시아태평양 : 국가별 분석
제9장 남미의 스타가르트병 치료제 시장 전망
- 시장 규모 및 예측
- 시장 점유율과 예측
- 남미 : 국가별 분석
제10장 중동 및 아프리카의 스타가르트병 치료제 시장 전망
- 시장 규모 및 예측
- 시장 점유율과 예측
- 중동 및 아프리카 : 국가별 분석
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트
- 쿠웨이트
제11장 시장 역학
제12장 시장 동향과 발전
제13장 Porter's Five Forces 분석
- 업계내 경쟁
- 신규 참여의 가능성
- 공급업체의 능력
- 고객의 능력
- 대체품의 위협
제14장 경쟁 구도
- Kubota Pharmaceutical Holdings Co Ltd
- IVERIC bio Inc
- Sanofi SA
- Alkeus Pharmaceuticals Inc
- Astellas Pharma Inc
- Cha Biotech Co Ltd/Old
- reVision Therapeutics, Inc.
- Biogen Inc
- F Hoffmann-La Roche AG
- Ocugen Inc
제15장 전략적 제안
제16장 조사 회사 소개 및 면책사항
ksm
Global Stargardt Disease Therapeutics Market was valued at USD 202.75 million in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.50% through 2030. In Stargardt disease, an inherited eye condition, the macula, which plays a crucial role in clear central vision, is adversely affected. This condition typically manifests in childhood or adolescence and gradually leads to a decline in visual acuity. While there are currently no approved treatments for Stargardt disease, significant progress has been made in the development of therapeutic approaches aimed at managing the condition and potentially arresting its progression. For instance, in 2023, WHO reported that over 2.2 billion people worldwide have vision impairment, with at least 1 billion cases preventable or unaddressed. The primary causes of blindness and vision loss globally are refractive errors and cataracts, highlighting the urgent need for improved eye care and preventive measures.
| Market Overview |
|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 202.75 Million |
| Market Size 2030 | USD 310.41 Million |
| CAGR 2025-2030 | 7.50% |
| Fastest Growing Segment | LBS-008 |
| Largest Market | North America |
Key Market Drivers
Increased Prevalence and Awareness
The prevalence of Stargardt Disease has been on the rise, with an increasing number of individuals being diagnosed with this condition worldwide. While it remains a rare disease, the broader global population and improved diagnostic capabilities have led to more cases being identified. This heightened prevalence underscores the urgency of finding effective treatments and therapies for those affected. For instance, in 2025, Ascidian Therapeutics has received FDA authorization to begin a Phase 1/2 clinical trial for ACDN-01, its RNA editing therapy for Stargardt disease, a genetic eye disorder caused by ABCA4 mutations. Unlike traditional gene therapies, ACDN-01 rewrites RNA exons to restore healthy protein production, potentially benefiting many affected individuals.
Stargardt Disease primarily affects children and young adults, but the ageing population has also contributed to its increasing prevalence. As the global population continues to age, the demand for treatments for age-related eye conditions, including Stargardt Disease, is expected to grow significantly. This demographic shift amplifies the market potential for Stargardt Disease therapeutics.
Key Market Challenges
Limited Understanding of the Disease Mechanism
Despite significant progress, our understanding of the exact mechanisms underlying Stargardt Disease remains incomplete. This knowledge gap can impede the development of targeted therapies and necessitates ongoing research to uncover the complexities of the condition.
Key Market Trends
Gene Therapy Breakthroughs
Gene therapy is emerging as a promising avenue in the quest to treat Stargardt Disease. Researchers are conducting clinical trials to test the safety and efficacy of gene therapies that aim to replace or correct the faulty genes responsible for the condition. As trials progress, breakthroughs that bring gene therapy closer to becoming a viable treatment option are likely to come up.
Key Market Players
- Kubota Pharmaceutical Holdings Co Ltd
- IVERIC bio Inc
- Sanofi SA
- Alkeus Pharmaceuticals Inc
- Astellas Pharma Inc
- Cha Biotech Co Ltd/Old
- reVision Therapeutics, Inc.
- Biogen Inc
- F Hoffmann-La Roche AG
- Ocugen Inc
Report Scope:
In this report, the Global Stargardt Disease Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Stargardt Disease Therapeutics Market, By Drug Type:
Stargardt Disease Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Stargardt Disease Therapeutics Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Stargardt Disease Therapeutics Market.
Available Customizations:
Global Stargardt Disease Therapeutics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Stargardt Disease Therapeutics Market Outlook
- 5.1. Market Size & Forecast
- 5.2. Market Share & Forecast
- 5.2.1. By Drug Type (LBS-008, Emixustat)
- 5.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
- 5.2.3. By Region
- 5.2.4. By Company (2024)
- 5.3. Product Market Map
- 5.3.1. By Drug Type
- 5.3.2. By Distribution Channel
- 5.3.3. By Region
6. North America Stargardt Disease Therapeutics Market Outlook
- 6.1. Market Size & Forecast
- 6.2. Market Share & Forecast
- 6.2.1. By Drug Type (LBS-008, Emixustat)
- 6.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
- 6.2.3. By Country
- 6.3. North America: Country Analysis
- 6.3.1. United States Stargardt Disease Therapeutics Market Outlook
- 6.3.1.1. Market Size & Forecast
- 6.3.1.2. Market Share & Forecast
- 6.3.1.2.1. By Drug Type
- 6.3.1.2.2. By Distribution Channel
- 6.3.2. Canada Stargardt Disease Therapeutics Market Outlook
- 6.3.2.1. Market Size & Forecast
- 6.3.2.2. Market Share & Forecast
- 6.3.2.2.1. By Drug Type
- 6.3.2.2.2. By Distribution Channel
- 6.3.3. Mexico Stargardt Disease Therapeutics Market Outlook
- 6.3.3.1. Market Size & Forecast
- 6.3.3.2. Market Share & Forecast
- 6.3.3.2.1. By Drug Type
- 6.3.3.2.2. By Distribution Channel
7. Europe Stargardt Disease Therapeutics Market Outlook
- 7.1. Market Size & Forecast
- 7.2. Market Share & Forecast
- 7.2.1. By Drug Type (LBS-008, Emixustat)
- 7.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
- 7.2.3. By Country
- 7.3. Europe: Country Analysis
- 7.3.1. Germany Stargardt Disease Therapeutics Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Drug Type
- 7.3.1.2.2. By Distribution Channel
- 7.3.2. United Kingdom Stargardt Disease Therapeutics Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Drug Type
- 7.3.2.2.2. By Distribution Channel
- 7.3.3. France Stargardt Disease Therapeutics Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Drug Type
- 7.3.3.2.2. By Distribution Channel
- 7.3.4. Italy Stargardt Disease Therapeutics Market Outlook
- 7.3.4.1. Market Size & Forecast
- 7.3.4.2. Market Share & Forecast
- 7.3.4.2.1. By Drug Type
- 7.3.4.2.2. By Distribution Channel
- 7.3.5. Spain Stargardt Disease Therapeutics Market Outlook
- 7.3.5.1. Market Size & Forecast
- 7.3.5.2. Market Share & Forecast
- 7.3.5.2.1. By Drug Type
- 7.3.5.2.2. By Distribution Channel
8. Asia-Pacific Stargardt Disease Therapeutics Market Outlook
- 8.1. Market Size & Forecast
- 8.2. Market Share & Forecast
- 8.2.1. By Drug Type (LBS-008, Emixustat)
- 8.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
- 8.2.3. By Country
- 8.3. Asia-Pacific: Country Analysis
- 8.3.1. China Stargardt Disease Therapeutics Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Drug Type
- 8.3.1.2.2. By Distribution Channel
- 8.3.2. Japan Stargardt Disease Therapeutics Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Drug Type
- 8.3.2.2.2. By Distribution Channel
- 8.3.3. India Stargardt Disease Therapeutics Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Drug Type
- 8.3.3.2.2. By Distribution Channel
- 8.3.4. Australia Stargardt Disease Therapeutics Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Drug Type
- 8.3.4.2.2. By Distribution Channel
- 8.3.5. South Korea Stargardt Disease Therapeutics Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Drug Type
- 8.3.5.2.2. By Distribution Channel
9. South America Stargardt Disease Therapeutics Market Outlook
- 9.1. Market Size & Forecast
- 9.2. Market Share & Forecast
- 9.2.1. By Drug Type (LBS-008, Emixustat)
- 9.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
- 9.2.3. By Country
- 9.3. South America: Country Analysis
- 9.3.1. Brazil Stargardt Disease Therapeutics Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Drug Type
- 9.3.1.2.2. By Distribution Channel
- 9.3.2. Argentina Stargardt Disease Therapeutics Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Drug Type
- 9.3.2.2.2. By Distribution Channel
- 9.3.3. Colombia Stargardt Disease Therapeutics Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Drug Type
- 9.3.3.2.2. By Distribution Channel
10. Middle East and Africa Stargardt Disease Therapeutics Market Outlook
- 10.1. Market Size & Forecast
- 10.2. Market Share & Forecast
- 10.2.1. By Drug Type (LBS-008, Emixustat)
- 10.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
- 10.2.3. By Country
- 10.3. MEA: Country Analysis
- 10.3.1. South Africa Stargardt Disease Therapeutics Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Drug Type
- 10.3.1.2.2. By Distribution Channel
- 10.3.2. Saudi Arabia Stargardt Disease Therapeutics Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Drug Type
- 10.3.2.2.2. By Distribution Channel
- 10.3.3. UAE Stargardt Disease Therapeutics Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Drug Type
- 10.3.3.2.2. By Distribution Channel
- 10.3.4. Kuwait Stargardt Disease Therapeutics Market Outlook
- 10.3.4.1. Market Size & Forecast
- 10.3.4.2. Market Share & Forecast
- 10.3.4.2.1. By Drug Type
- 10.3.4.2.2. By Distribution Channel
11. Market Dynamics
- 11.1. Drivers
- 11.2. Challenges
12. Market Trends & Developments
- 12.1. Recent Development
- 12.2. Mergers & Acquisitions
- 12.3. Product Launches
13. Porter's Five Forces Analysis
- 13.1. Competition in the Industry
- 13.2. Potential of New Entrants
- 13.3. Power of Suppliers
- 13.4. Power of Customers
- 13.5. Threat of Substitute Products
14. Competitive Landscape
- 14.1. Kubota Pharmaceutical Holdings Co Ltd
- 14.1.1. Business Overview
- 14.1.2. Product Offerings
- 14.1.3. Recent Developments
- 14.1.4. Financials (As Reported)
- 14.1.5. Key Personnel
- 14.1.6. SWOT Analysis
- 14.2. IVERIC bio Inc
- 14.3. Sanofi SA
- 14.4. Alkeus Pharmaceuticals Inc
- 14.5. Astellas Pharma Inc
- 14.6. Cha Biotech Co Ltd/Old
- 14.7. reVision Therapeutics, Inc.
- 14.8. Biogen Inc
- 14.9. F Hoffmann-La Roche AG
- 14.10.Ocugen Inc
15. Strategic Recommendations
16. About Us & Disclaimer
